-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Not long ago, there were rumors that Hutchison Medicine would conduct an IPO of US$500 million in Hong Kong stocks as early as the first half of this year.
In response, Hutchison Medicine responded that there are no plans for the time being, but it will continue to monitor market conditions
.
If related IPOs are launched in the future, cornerstone investors will be introduced
.
However, He Jun, CEO of Hutchison Pharmaceuticals, once stated at the company's performance meeting for the first half of 2020 that he hopes to sign an amendment to the sales rights of Fruquintinib with Eli Lilly and achieve the commercialization of Sofatinib after its listing.
After that, choose an opportunity to list in Hong Kong
.
In this view, it is only a matter of time before Hutchison Medicine goes public in Hong Kong
.
Reference materials:
The Paper: Hutchison Pharma responds to restarting Hong Kong stock IPOs: still discussing, science and technology innovation board is also considering scope
International Finance News: Hutchison Pharma achieves revenue of US$228 million in 2020, and Syvotinib is approved in the second quarter of this year